DEXTROMETHORPHAN HYDROCHLORIDE

US Approved OTC

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H25NO.ClH
Molecular Weight	307.858
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXTROMETHORPHAN HYDROCHLORIDE

Structure Search

SMILES

Cl.[H][C@]12CCCC[C@]13CCN(C)[C@H]2CC4=CC=C(OC)C=C34

InChI

InChIKey=SNDDIRAXSDUVKW-URVXVIKDSA-N

InChI=1S/C18H25NO.ClH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2694543 http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/25420446

Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099	Agonist 2678		205.0 nM [Ki]
Glutamate [NMDA] receptor subunit 3A 21 Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf	Primary		Approved 8429	MUCINEX DM Approved Use Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date 2004
Pseudobulbar affect 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000221	Primary		Approved 8429	NUEDEXTA Approved Use NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217	30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: healthy age: adults sex: food status:

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	unhealthy, 19-52 years n = 16 Health Status: unhealthy Condition: chronic intractable partial onset seizures Age Group: 19-52 years Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	Sources: https://pubmed.ncbi.nlm.nih.gov/8741125
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	unhealthy, 19-67 years n = 11 Health Status: unhealthy Condition: Huntington's disease Age Group: 19-67 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	Sources: https://pubmed.ncbi.nlm.nih.gov/2529964
120 mg single, oral Recommended Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	healthy, 26.5 years n = 40 Health Status: healthy Age Group: 26.5 years Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	Sources: https://pubmed.ncbi.nlm.nih.gov/26294136
900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	Other AEs: Ischemic colitis... Other AEs: Ischemic colitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Ataxia (1 patient) Nystagmus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

AEs

AE	Significance	Dose	Population
Ischemic colitis	1 patient	900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
Ataxia	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Lethargy	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Nystagmus	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882	P-gp 1537	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.eurekaselect.com/66423/article/lack-interaction-nmda-receptor-antagonists-dextromethorphan-and-dextrorphan-p	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4470	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4470
ZINC	ZINC000003201907	http://zinc15.docking.org/substances/ZINC000003201907

PubMed

Title	Date	PubMed
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist.	1991 Mar-Apr	1685312
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study].	2005	17037292
Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico.	2005	16416672
Epigenetic silencing of DSC3 is a common event in human breast cancer.	2005	16168112
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.	2005	16124035
Dextromethorphan psychosis, dependence and physical withdrawal.	2005 Dec	16318953
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.	2005 Jun	15988119
Dextromethorphan-induced delirium and possible methadone interaction.	2005 Mar	16089243
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.	2005 Nov	16222729
Side effects of dextromethorphan abuse, a case series.	2005 Sep	16122622
Cluster formation as a tool for development in Medicon Valley.	2006 Jan-Feb	16485399
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings.	2006 Jun 27	16801672
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.	2006 May	16634036
Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan.	2006 Nov-Dec	17102908
Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization.	2006 Sep	16865411
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.	2007	18096088
Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure.	2007	17903238
Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study.	2007 Apr	17488670
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.	2007 Apr	17225166
Effects of dextromethorphan on dopamine dependent behaviours in rats.	2007 Aug	17877148
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.	2007 Aug	17470523
Treatment of the common cold.	2007 Feb 15	17323712
A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism.	2007 Jan	17175572
Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain.	2007 Jul	17573115
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies.	2007 Jul	17565714
Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.	2007 Jul	17333164
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method].	2007 Jun	17702393
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.	2007 Jun 1	17543114
Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry.	2007 Jun 1	17267297
Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.	2007 May 9	17418993
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection.	2007 Nov 14	18000543
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007 Nov 14	17651725
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.	2007 Spring	17461892
Ubiquitous computing for remote cardiac patient monitoring: a survey.	2008	18604301
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems.	2008 Apr	18346904
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.	2008 Apr	18221780
Effects of common antitussive drugs on the hERG potassium channel current.	2008 Dec	19034038
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.	2008 Jan 8	18281903
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice.	2008 Jul	18500357
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening.	2008 Jul	18420780
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.	2008 Jul	18359183
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis.	2008 Sep	18336967
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice.	2009	19258215
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice.	2009 Apr 1	19189960
The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.	2009 Feb 18	19226451
Amyotrophic lateral sclerosis.	2009 Feb 3	19192301
Characterization of retrieved orthodontic miniscrew implants.	2009 Jan	19121491
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.	2009 Jan	19029129
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.	2009 Jan-Feb	19344034
[Bone anchored hearing aids (BAHA)].	2009 Mar	19343390

Patents

Sample Use Guides

In Vivo Use Guide

15-30 mg 3 to 4 times per day (cough) 20-30 mg twice daily (pseudobulbar affect)

Route of Administration: Oral

In Vitro Use Guide

In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.

Name

Type

Language

DEXTROMETHORPHAN HYDROCHLORIDE

Common Name

English

DEXTROMETHORPHAN HCL

Common Name

English

MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-, HYDROCHLORIDE

Common Name

English

Dextromethorphan hydrochloride [WHO-DD]

Common Name

English

DEXTROMETHORPHAN HYDROCHLORIDE [VANDF]

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID70940040